Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Antimicrob Agents Chemother. 2002 Nov;46(11):3381-5.

    Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.

    Source

    Institut für Medizinische Mikrobiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany. Wichelhaus@em.uni-frankfurt.de

    Abstract

    Resistance determinants that interfere with normal physiological processes in the bacterial cell usually cause a reduction in biological fitness. Fitness assays revealed that 17 of 18 in vitro-selected chromosomal mutations within the rpoB gene accounting for rifampin resistance in Staphylococcus aureus were associated with a reduction in the level of fitness. There was no obvious correlation between the level of resistance to rifampin and the level of fitness loss caused by rpoB mutations. Among 23 clinical rifampin-resistant S. aureus isolates from six countries, only seven different rpoB genotypes could be identified, whereby the mutation 481His-->Asn was present in 21 (91%) of these 23 isolates. The mutation 481His-->Asn, in turn, which confers low-level rifampin resistance on its own, was not shown to be associated with a cost of resistance in vitro. The restriction to distinct mutations that confer rifampin resistance in vivo, as demonstrated here, appears to be determined by the Darwinian fitness of the organisms.

    PMID:
    12384339
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC128759
    Free PMC Article

    Images from this publication.See all images (3)Free text

    FIG. 1.
    FIG. 3.
    FIG. 2.

      Supplemental Content

      Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk